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This study was initiated to determine whether 2 structurally related flavonoids found in Cyclopia 
subternata—vicenin-2 (VCN) and scolymoside (SCL)—could modulate renal functional damage 
in a mouse model of sepsis, and to elucidate the relevant underlying mechanisms. The potential 
of VCN and SCL treatment to reduce renal damage induced by cecal ligation and puncture (CLP) 
surgery in mice was measured via assessment of serum creatinine, blood urea nitrogen (BUN), lipid 
peroxidation, total glutathione, glutathione peroxidase activity, catalase activity, and superoxide 
dismutase activity. Treatment with either VCN or SCL resulted in elevated plasma levels of BUN and 
creatinine, and of protein in the urine of mice with CLP-induced renal damage. Moreover, both VCN 
and SCL inhibited nuclear factor κB activation and reduced the induction of nitric oxide synthase 
and excessive production of nitric acid. VCN and SCL treatment also reduced the plasma levels of 
interleukin-6, and tumor necrosis factor-α, reduced lethality due to CLP-induced sepsis, increased 
lipid peroxidation, and markedly enhanced the antioxidant defense system by restoring the levels 
of superoxide dismutase, glutathione peroxidase, and catalase in kidney tissues. The present results 
suggest that VCN and SCL protect mice from sepsis-triggered renal injury.
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INTRODUCTION
Sepsis is a serious infection that causes severe 
inflammatory responses and is associated with a high 
level of mortality despite recent advances in critical 
care (Russell, 2006). Cytokine activation is part of the 
host defense system against infection, but the excessive 
production of cytokines can cause extensive damage 
and multiple organ failure (MOF) (Chaudhry et al., 
2013). Sepsis induces the activation of inducible nitric 
oxide synthase (iNOS) and upregulates the production 
of nitric oxide (NO) and reactive oxygen species 
(ROS), leading to cellular toxicity (Parratt, 1998; 
Symeonides and Balk, 1999). Sepsis-induced MOF 
may be reduced by inhibiting inflammatory cytokine 
production and iNOS activity (Draisma et al., 2010; 
Parratt, 1998; Symeonides, Balk, 1999). In addition, the 
overproduction of ROS can cause oxidative stress, as 
indicated by a decrease in the endogenous antioxidant 
defense system and lipid peroxidation. Therefore, new 
drug candidates that inhibit the production of ROS and 
inflammatory cytokines may help in the management of 
severe sepsis or septic shock (Cadenas, Cadenas, 2002; 
Vincent et al., 2000). 
Tea and herbal infusions are natural beverages 
containing compounds that are of particular interest 
to the health sciences owing to their potential in vivo 
biological properties (Prior, Cao, 1999; Warren, 1999). 
Health-promoting properties such as antioxidant, 
anti-inflammatory, and memory-enhancing activities 
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have been documented for active compounds found 
in Cyclopia subternata, Peperomia blanda, Ocimum 
sanctum, Perilla frutescens, Urtica circularis, and 
Potentilla discolor (Islam et al., 2014; Joubert et al., 
2011; Leiro et al., 2003; Pardo Andreu et al., 2010; 
Sanchez et al., 2000). C. subternata is known to contain 
abundant flavonoids, particularly vicenin-2 (VCN) and 
scolymoside (SCL) (Kazuno et al., 2005). Furthermore, 
previous reports have shown that VCN exerts anti-
diabetic, anti-glycation, and anti-inflammatory activities 
(Islam et al., 2014; Marrassini et al., 2011). However, the 
beneficial effects of VCN and SCL on sepsis-induced 
renal damage have not yet been studied. Therefore, in 
this study, we investigated the renal protective effects of 
VCN and SCL in an animal model of sepsis. 
MATERIAL AND METHODS 
Animals and sepsis mouse model
Before cecal ligation and puncture (CLP) surgery, 
male C57BL/6 mice (average weight 27 g; Sungnam, 
Republic of Korea) were anesthetized using Rompum 
(xylazine, 10 mg/kg) and Zoletil (30 mg/kg). The CLP-
induced sepsis mouse model was developed as previously 
described (Bae et al., 2014; Wang et al., 2004), and 
sham-operated animals were used as controls. Animals 
were randomly divided into the following groups (n = 10 
each): sham-operated control; VCN or SCL only (1.2 mg/
kg body weight; Sigma-Aldrich, St. Louis, MO, USA), 
administrated in 0.5% dimethyl sulfoxide (DMSO); CLP 
surgery only; and CLP + VCN or SCL (0.3, 0.6, or 1.2 
mg/kg body weight). VCN and SCL were intravenously 
injected 12 h after CLP and again 50 h after CLP. Blood 
and organ samples were collected 4 days after VCN or 
SCL injection for functional assays. This protocol was 
approved by the Animal Care Committee at Kyungpook 
National University prior to conducting the study (IRB 
No. KNU 2017-102). 
Cell culture 
Primary human umbilical vein endothelial cells 
(HUVECs) were purchased from Cambrex Bio Science 
(Charles City, IA, USA), maintained as previously 
described (Jung et al., 2016; Kim, Bae, 2016), and used 
after three to five passages. 
Sample preparation and evaluation of 
nephrotoxicity and lactate dehydrogenase (LDH)
Four days after VCN or SCL injection, blood, 
urine, and kidney samples were collected and prepared 
as previously described (Lee et al., 2017). Renal 
dysfunctional markers, such as BUN and creatinine, 
and a tissue injury marker (LDH) were measured as 
previously described (Lee et al., 2017). 
Plasma nitrite/nitrate determination
Levels of nitrite and nitrate in the plasma were 
determined using Griess reagents and vanadium solution 
(VCl3), as previously described (Lee et al., 2017; 
Miranda, Espey, Wink, 2001). Briefly, each sample (100 
µL) was mixed with VCl3 (100 µL) and incubated with 
Griess reagents. After 30 min, the optical density was 
measured at 540 nm (OD540nm) and a change in color 
was monitored. Sodium nitrite standards were used to 
prepare a standard curve to measure the final nitrite/
nitrate concentrations. 
Determination of tumor necrosis factor-
alpha (TNF-α), interleukin (IL)-6, and renal 
myeloperoxidase (MPO) activity via enzyme-
linked immunosorbent assays (ELISA) 
Levels of IL-6, TNF-α (R&D Systems, 
Minneapolis, MN, USA), and MPO (Abcam, Cambridge, 
UK) in plasma were determined using commercially 
available ELISA kits. 
Evaluation of oxidative stress markers
Lipid peroxidation, malondialdehyde (MDA), 
total glutathione (GSH), superoxide dismutase (SOD), 
glutathione peroxidase (GSH-Px), and catalase activities 
(CAT) were measured as described previously (Beutler, 
Duron, Kelly, 1963; Lee et al., 2017). 
Western blotting 
Kidney samples were prepared and western blotting 
using primary antibodies for iNOS, inhibitor of kappa B 
(IκB), nuclear factor-kappa B (NF-κB), and b-actin was 
conducted as previously described (Lee et al., 2017). 
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Cell viability assay
Cellular viability was measured via 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) 
assay, as previously described (Lee et al., 2017). HU-
VECs were incubated with VCN or SCL for 48 h. 
RESULTS
VCN and SCL reduced CLP-induced renal tissue 
injury and plasma nitrite and nitrate production
CLP surgery increased nephrotoxic markers 
levels (Table I), such as BUN and creatinine in blood, 
and protein concentrations in the urine compared to 
those in the sham-operated group, all of which were 
reduced by administration of VCN and SCL (0.3, 0.6, 
or 1.2 mg/kg, 12 h and 50 h after CLP). Levels of LDH, 
a marker of general tissue injury, were also reduced by 
VCN and SCL treatment in CLP-operated mice (Table 
I). In addition, the effects of VCN and SCL treatment 
on the inflammatory response in kidney tissue were 
investigated in vivo by measuring plasma nitrite 
and nitrate levels (stable end products of NO). NO 
production in CLP-operated mice was significantly 
increased (7.3-fold) compared to that in the control 
group (Table II), and was reduced by treatment with 
VCN or SCL (Table II). 
TABLE I - Effects of VCN or SCL treatment on plasma levels of BUN and creatinine and urine level of protein in CLP-operated 
micea
BUN (mg/dL) Creatinine (mg/dL) Urine protein (mg/12 hour) LDH (U/dL)
Sham 14.6 ± 0.6 0.118 ± 0.02 2.3 ± 0.21 256 ± 15.27
VCN
(1.2 mg/kg)
14.9 ± 0.5 0.125 ± 0.01 2.1 ± 0.25 265 ± 14.9
SCL
(1.2 mg/kg)
15.2 ± 0.4 0.123 ± 0.02 2.2 ± 0.27 259 ± 20.3
CLP 78.9 ± 4.3 0.425 ± 0.03 13.9 ± 0.57 3570 ± 150.8
CLP + VCN
(0.3 mg/kg)
77.5 ± 3.5 0.431 ± 0.02 13.6 ± 0.42 3380 ± 210.4
CLP + VCN
(0.6 mg/kg)
55.3 ± 4.7* 0.289 ± 0.02* 7.2 ± 0.52* 2250 ± 150.5*
CLP + VCN
(1.2 mg/kg)
30.2 ± 2.5* 0.215 ± 0.02* 3.9 ± 0.23* 1280 ± 125.3*
CLP + SCL
(0.3 mg/kg)
75.6 ± 4.3 0.422 ± 0.03 13.2 ± 0.31 3480 ± 250.9
CLP + SCL
(0.6 mg/kg)
59.2 ± 3.9* 0.275 ± 0.03* 6.9 ± 0.47* 2580 ± 120.4*
CLP + SCL
(1.2 mg/kg)
32.5 ± 3.1* 0.202 ± 0.02* 3.5 ± 0.31* 1350 ± 102.2*
aEach value represents the mean ± SD (n = 10). 
Sham, sham-operated mice; VCN or SCL, mice treated with VCN or SCL (1.2 mg/kg body weight) at 12 and 50 h; CLP, CLP-
operated mice; VCN or SCL + CLP, mice treated with PEL at 12 and 50 h after CLP surgery. 
* p < 0.05 as compared to CLP.
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TABLE II - Effects of VCN or SCL treatment on NO, TNF-, IL-6 levels and renal MPO activity in CLP-operated micea
NO (mM) TNF-a (pg/mL) IL-6 (pg/mL) MPO (U/g tissue)
Sham 30.8 ± 2.5 111.3 ± 8.6 0.69 ± 0.06 0.59 ± 0.04
VCN
(1.2 mg/kg)
31.5 ± 3.1 121.5 ± 8.9 0.72 ± 0.05 0.58 ± 0.05
SCL
(1.2 mg/kg)
30.9 ± 2.8 123.8 ± 10.2 0.71 ± 0.04 0.52 ± 0.06
CLP 218.9 ± 15.3 528.4± 41.9 75.42 ± 6.15 3.42 ± 0.32
CLP + VCN
(0.3 mg/kg)
220.2 ± 18.7 535.6 ± 35.3 79.71 ± 5.83 3.59 ± 0.41
CLP + VCN
(0.6 mg/kg)
156.4 ± 12.5* 301.7 ± 21.3* 43.25 ± 4.11* 2.37 ± 0.25*
CLP + VCN
(1.2 mg/kg)
85.8 ± 7.3* 185.9 ± 14.7* 22.64 ± 2.32* 1.19 ± 0.17*
CLP + SCL
(0.3 mg/kg)
215.4 ± 12.9 531.5 ± 31.4 78.52 ± 6.12 3.47 ± 0.39
CLP + SCL
(0.6 mg/kg)
170.3 ± 13.1* 310.4 ± 25.7* 45.19 ± 3.15* 2.41 ± 0.31*
CLP + SCL
(1.2 mg/kg)
82.9 ± 6.2* 175.4 ± 11.8* 23.57 ± 2.18* 1.25 ± 0.11*
aEach value represents the mean ± SD (n = 10). 
Sham, sham-operated mice; VCN or SCL, mice treated with VCN or SCL (1.2 mg/kg body weight) at 12 and 50 h; CLP, CLP-
operated mice; VCN or SCL + CLP, mice treated with PEL at 12 and 50 h after CLP surgery. 
* p < 0.05 as compared to CLP.
VCN and SCL inhibited TNF-α, IL-6, MPO, 
and MDA levels induced by CLP
Next, we determined the effects of VCN and SCL 
on inflammatory markers such as TNF-α and IL-6. 
Treatment with VCN and SCL inhibited CLP-induced 
production of TNF-α and IL-6 in plasma (Table II). 
Next, we tested the effects of VCN and SCL on the 
infiltration of neutrophils by measuring MPO levels (an 
indicator of renal infiltration by neutrophils) after CLP 
surgery. We identified a marked increase in MPO levels 
after CLP surgery (Table II), which was associated with 
nephritis. Post-surgical treatment with VCN or SCL 
resulted in significantly lower MPO concentrations 
in renal tissues than in CLP-operated mice. We also 
determined the effects of VCN and SCL on MDA, an 
indicator of lipid peroxidation levels. Increased MDA 
levels induced by CLP were reduced by treatment with 
VCN or SCL (Table III). 
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Sham 187.6 ± 12.3 26.9 ± 2.3 1.02 ± 0.07 2.39 ± 0.15 4.12 ± 0.37
VCN
(1.2 mg/kg)
182.9 ± 13.4 27.1 ± 1.9 1.09 ± 0.08 2.41 ± 0.22 4.31 ± 0.32
SCL
(1.2 mg/kg)
184.5 ± 12.7 27.5 ± 1.8 1.06 ± 0.11 2.43 ± 0.27 4.25 ± 0.36
CLP 312.5 ± 25.2 16.8 ± 1.4 0.72 ± 0.06 1.39 ± 0.12 2.58 ± 0.21
CLP + VCN
(0.3 mg/kg)
308.4 ± 22.7 17.1 ± 1.2 0.75 ± 0.07 1.44 ± 0.14 2.62 ± 0.31
CLP + VCN
(0.6 mg/kg)
275.4 ± 13.5* 19.7 ± 1.4* 0.87 ± 0.08* 1.75 ± 0.14* 3.28 ± 0.29*
CLP + VCN
(1.2 mg/kg)
212.7 ± 18.2* 23.5 ± 2.0* 0.98 ± 0.06* 2.02 ± 0.17* 3.85 ± 0.24*
CLP + SCL
(0.3 mg/kg)
311.3 ± 21.8 17.2 ± 1.7 0.73 ± 0.06 1.49 ± 0.21 2.67 ± 0.25
CLP + SCL
(0.6 mg/kg)
283.7 ± 14.7* 20.4 ± 1.7* 0.82 ± 0.06* 1.86 ± 0.15* 3.31 ± 0.21*
CLP + SCL
(1.2 mg/kg)
223.7 ± 21.4* 24.9 ± 2.2* 0.95 ± 0.08* 2.11 ± 0.14* 3.92 ± 0.34*
aEach value represents the mean ± SD (n = 10). 
Sham, sham-operated mice; VCN or SCL, mice treated with VCN or SCL (1.2 mg/kg body weight) at 12 and 50 h; CLP, CLP-
operated mice; VCN or SCL + CLP, mice treated with PEL at 12 and 50 h after CLP surgery. 
* p < 0.05 as compared to CLP.
VCN and SCL increased total GSH and antioxidant 
enzyme activity in the kidney tissues
We determined whether VCN and SCL could 
control CLP-induced oxidative stress by measuring 
antioxidant GSH levels and activities of the oxidative 
stress-associated enzymes SOD, GSH-Px, and CAT. 
Total GSH levels and the activities of SOD, GSH-Px, 
and CAT were similar to those in the VCN only, SCL 
only, and sham-operated groups. In contrast, the total 
GSH levels and renal activities of all three enzymes 
were reduced in CLP-operated mice and were increased 
by treatment with VCN or SCL (Table III). 
VCN and SCL reduced renal proteins and 
iNOS levels, and inhibited NF-κB activity
We investigated the levels of iNOS, IκB, and NF-
κB to define the underlying renal protective effects of 
VCN and SCL. Elevated protein levels of iNOS by CLP 
were dramatically reduced by treatment with VCN 
or SCL (Figure 1). Next, we determined the effects 
Bong-Seon Lee, Sumin Yang, Changhun Lee, Sae-Kwang Ku, Jong-Sup Bae
Page 6/9 Braz. J. Pharm. Sci. 2020;56: e18636
of VCN and SCL on IκB degradation by CLP and 
translocation of NF-κB in the cell. CLP-induced IκB 
degradation was significantly lowered by treatment 
with VCN or SCL and decreased levels of NF-κB p65 
in the cytosol were reversed by treatment with VCN 
or SCL (Figure 1A). In addition, the cellular toxicity 
of VCN and SCL was determined via MTT assay, 
showing that neither VCN nor SCL affected cellular 
viability when administered at concentrations up to 
100 µM (Figure 1B).
FIGURE 1 - Effects of vicenin-2 (VCN) and scolymoside (SCL) treatment on renal inducible nitric oxide synthase (iNOS), 
inhibitor of kappa B (IκB), and nuclear factor-kappa B (NF-κB) expression in cecal ligation and puncture (CLP)-operated mice. 
(A) Sham-operated mice; CLP-operated mice; mice treated with VCN or SCL (1.2 mg/kg body weight) 12 h and 50 h after CLP 
surgery (from left line). Western blots of iNOS, IκB, NF-κB, and b-actin. The image is representative of results obtained from 
three different experiments. (B) The effects of VCN and SCL on cellular viability were measured via MTT assay. D = 0.2% 
dimethyl sulfoxide (DMSO), used as the vehicle control. The results are shown as means ± SD from three separate experiments 
on different days performed in triplicate. 
VCN and SCL reduced CLP-induced septic lethality
To confirm the renal protective effects of VCN 
and SCL, we tested their effects on CLP-induced 
lethality. Data showed that injection with VCN or SCL 
(1.2 mg/kg, 12 h and 50 h after CLP) increased the 
survival rate (50%) of CLP-operated mice (p < 0.0001, 
Figure 2). 
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FIGURE 2 - Effects of VCN and SCL on CLP-induced septic lethality. Male C57BL/6 mice (n = 20) were administered VCN or 
SCL at 1.2 mg/kg (intravenous, i.v.) 12 h and 50 h after CLP. Animal survival was monitored every 12 h for 132 h after CLP. 
Control CLP-operated mice () and sham-operated mice () were administered sterile saline (n = 20). Kaplan-Meier survival 
analysis was used to determine the overall survival rates versus treated CLP-operated mice.
DISCUSSION
In this study, we report that: (1) the expression 
of plasma BUN and creatinine and urine protein 
levels were increased by CLP, but decreased by VCN 
and SCL treatment; (2) CLP increased renal tissue 
injury inflammatory protein markers, and treatment 
with VCN and SCL reduced these levels; (3) CLP-
operated mice showed increased NO production in the 
blood and iNOS expression, which was significantly 
attenuated by treatment with VCN or SCL; and (4) 
VCN and SCL increased GSH and antioxidant enzyme 
activity. Therefore, the renal protective effects of VCN 
and SCL were mediated by reducing NO production 
and inflammatory protein levels, and increasing 
antioxidant enzymes. 
It is well known that levels of TNF-α, IL-6, and 
NF-κB are increased under severe inflammatory 
conditions (Chaudhry et al., 2013; Stearns-Kurosawa 
et al., 2011). Based on the current findings that VCN 
and SCL inhibited the upregulation of TNF- α and 
IL-6, and NF-κB by CLP, we concluded that the renal 
protective effects of VCN and SCL were mediated by 
suppressing inflammatory gene expression. When 
cells are activated by inflammatory mediators, NF-κB 
dissociates from IκB and translocates to the nucleus 
(Oeckinghaus, Ghosh, 2009). NF-κB is a potential 
primary target for inflammatory diseases, as the renal 
protective mechanisms of VCN and SCL were mediated 
by inhibiting the degradation of IκB and the CLP-
mediated activation of NF-κB.
Genes encoding three antioxidant enzymes 
(SOD, CAT, and GSH-Px) are regarded as the primary 
oxidative defense genes (Birben et al., 2012). CLP 
surgery lowered the expression levels of SOD, CAT, 
and GSH-Px, but these were significantly increased 
by VCN and SCL treatment, indicating that these 
exert cytoprotective effects on CLP-induced oxidative 
damage in renal tissues. CLP also increased renal MDA 
concentrations, a major lipid peroxidation product and 
oxidative stress marker (Qiao et al., 2011; Xiao et al., 
2012; Zhang et al., 2011), and these were reduced by 
VCN and SCL administration. Therefore, VCN and 
SCL protected against CLP-induced oxidative stress 
and injury through suppression of lipid peroxidation and 
activation of antioxidant enzymes. 
Intravenously injected VCN or SCL (1.2 mg/
kg) showed renal protective functions against CLP-
induced responses. Considering that the average 
weight of mice used in this study was 27 g and the 
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average weight of an adult human is 70 kg, we would 
require 84 mg of VCN or SCL to achieve renal 
protective effects if the compound is administrated 
intravenously in humans. However, if the compounds 
are ingested through herbal tea, an amount greater 
than this would be needed for the following reasons: 
1) large differences exist between intravenous 
injection and the oral route; 2) after ingesting the tea, 
several pharmacological processes are required for the 
compound (VCN or SCL) to reach the bloodstream, 
such as absorption, distribution, metabolism, and 
excretion (ADME); and 3) the entire content of the 
compound in the herbal tea is not absorbed. In order for 
a consumed compound to be effectively utilized by the 
body’s vascular system, these four processes (ADME), 
which represent the distribution of a pharmaceutical 
compound within an organism, must be optimized. 
These properties influence the compound levels and 
the kinetics of exposure of the tissues to the compound; 
hence, these criteria influence the performance and 
pharmacological activity of the compound. 
Collectively, our data have demonstrated the renal 
protective effects of VCN and SCL against sepsis. The 
beneficial activities of VCN and SCL were accompanied 
by lower levels of TNF-α, IL-6, iNOS, and NO, via 
inhibition of the NF-κB signaling pathway, which is 
associated with increased antioxidant defenses and 
decreased lipid peroxidation in vivo. Therefore, VCN and 
SCL show potential for therapeutic use in the treatment 
of renal inflammatory diseases. 
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